Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBrainstorm Cell Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.53 | -$0.53 | -$0.53 |
| Q2 2024 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q3 2024 | 1 | -$0.27 | -$0.27 | -$0.27 |
Brainstorm Cell Therapeutics Inc. Earnings Date And Information
Brainstorm Cell Therapeutics Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-1.8 earnings per share for the quarter, missing analysts' consensus estimates of $-0.45 by $1.35. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Brainstorm Cell Therapeutics Inc. has generated $0 earnings per share over the last year ($-0.4 diluted earnings per share) and currently has a price-to-earnings ratio of -0.85. Brainstorm Cell Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Brainstorm Cell Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.45 | -$0.51 | -0.06 | $0 | $0 |
| 08/14/2024 | Q2 2024 | -$0.60 | -$0.54 | 0.06 | $365,000 | $365,000 |
| 05/14/2024 | Q1 2024 | -$0.05 | $-569,000 | |||
| 04/01/2024 | Q4 2023 | -$2.25 | -$0.11 | 2.14 | $343,000 | |
| 09/29/2023 | Q3 2023 | -$0.03 | $0 | |||
| 08/14/2023 | Q2 2023 | -$2.25 | -$0.13 | 2.12 | $154,000 | |
| 05/15/2023 | Q1 2023 | -$0.14 | $-497,000 | |||
| 03/30/2023 | Q4 2022 | -$2.70 | -$0.14 | 2.56 | $0 | |
| 11/14/2022 | Q3 2022 | -$2.25 | -$0.19 | 2.06 | $474,000 | |
| 08/15/2022 | Q2 2022 | -$2.25 | -$0.18 | 2.07 | $204,000 | |
| 05/16/2022 | Q1 2022 | -$1.95 | -$0.14 | 1.81 | $340,000 | |
| 03/28/2022 | Q4 2021 | -$3.00 | -$0.17 | 2.83 | $0 | |
| 11/15/2021 | Q3 2021 | -$3.15 | -$0.15 | 3 | $0 | |
| 08/05/2021 | Q2 2021 | -$3.00 | -$0.17 | 2.83 | $87,000 | |
| 04/26/2021 | Q1 2021 | -$4.05 | -$0.19 | 3.86 | $501,000 | |
| 02/04/2021 | Q4 2020 | -$7.20 | -$0.33 | 6.87 | $0 | |
| 10/15/2020 | Q3 2020 | -$3.60 | -$0.14 | 3.46 | $0 | |
| 08/05/2020 | Q2 2020 | -$3.60 | -$0.25 | 3.35 | $823,000 | |
| 05/07/2020 | Q1 2020 | -$3.45 | -$0.29 | 3.16 | $0 | |
| 02/18/2020 | Q4 2019 | -$3.15 | -$0.27 | 2.88 | $-366,000 |
Brainstorm Cell Therapeutics Inc. Earnings: FAQ's
When is Brainstorm Cell Therapeutics Inc.'s earnings date?
Brainstorm Cell Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates.
How can I listen to Brainstorm Cell Therapeutics Inc.'s earnings conference
call?
The conference call for Brainstorm Cell Therapeutics Inc.'s latest earnings report can be listened to online.
How can I read Brainstorm Cell Therapeutics Inc.'s conference call transcript?
The conference call transcript for Brainstorm Cell Therapeutics Inc.'s latest earnings report can be read online.
How much profit does Brainstorm Cell Therapeutics Inc. generate each year?
Brainstorm Cell Therapeutics Inc. (:BCLI) has a recorded net income of $0. Brainstorm Cell Therapeutics Inc. has generated $-0.4 earnings per share over the last four quarters.
What is Brainstorm Cell Therapeutics Inc.'s price-to-earnings ratio?
Brainstorm Cell Therapeutics Inc. (:BCLI) has a price-to-earnings ratio of -0.85 and price/earnings-to-growth ratio is 0.01.